Category: Nevin Manimala

J Med Internet Res. 2024 Oct 29;26:e51269. doi: 10.2196/51269.

ABSTRACT

BACKGROUND: Passive sensing through smartphone keyboard data can be used to identify and monitor symptoms of mood disorders with low participant burden. Behavioral phenotyping based on mobile keystroke data can aid in clinical decision-making and provide insights into the individual symptoms of mood disorders.

OBJECTIVE: This study aims to derive digital phenotypes based on smartphone keyboard backspace use among 128 community adults across 2948 observations using a Bayesian mixture model.

METHODS: Eligible study participants completed a virtual screening visit where all eligible participants were instructed to download the custom-built BiAffect smartphone keyboard (University of Illinois). The BiAffect keyboard unobtrusively captures keystroke dynamics. All eligible and consenting participants were instructed to use this keyboard exclusively for up to 4 weeks of the study in real life, and participants’ compliance was checked at the 2 follow-up visits at week 2 and week 4. As part of the research protocol, every study participant underwent evaluations by a study psychiatrist during each visit.

RESULTS: We found that derived phenotypes were associated with not only the diagnoses and severity of depression and mania but also specific individual symptoms. Using a linear mixed-effects model with random intercepts accounting for the nested data structure from daily data, the backspace rates on the continuous scale did not differ between participants in the healthy control and in the mood disorders groups (P=.11). The 3-class model had mean backspace rates of 0.112, 0.180, and 0.268, respectively, with a SD of 0.048. In total, 3 classes, respectively, were estimated to comprise 37.5% (n=47), 54.4% (n=72), and 8.1% (n=9) of the sample. We grouped individuals into Low, Medium, and High backspace rate groups. Individuals with unipolar mood disorder were predominantly in the Medium group (n=54), with some in the Low group (n=27) and a few in the High group (n=6). The Medium group, compared with the Low group, had significantly higher ratings of depression (b=2.32, P=.008). The High group was not associated with ratings of depression with (P=.88) or without (P=.27) adjustment for medication and diagnoses. The High group, compared with the Low group, was associated with both nonzero ratings (b=1.91, P=.02) and higher ratings of mania (b=1.46, P<.001). The High group, compared with the Low group, showed significantly higher odds of elevated mood (P=.03), motor activity (P=.04), and irritability (P<.05).

CONCLUSIONS: This study demonstrates the promise of mobile typing kinematics in mood disorder research and practice. Monitoring a single mobile typing kinematic feature, that is, backspace rates, through passive sensing imposes a low burden on the participants. Based on real-life keystroke data, our derived digital phenotypes from this single feature can be useful for researchers and practitioners to distinguish between individuals with and those without mood disorder symptoms.

PMID:39471368 | DOI:10.2196/51269

J Med Internet Res. 2024 Oct 29;26:e58591. doi: 10.2196/58591.

ABSTRACT

BACKGROUND: To date, no randomized controlled trials have specifically addressed behavior changes after HIV self-testing (HIVST) among transgender women.

OBJECTIVE: This study aims to evaluate the effects of HIVST on changes in HIV testing behavior, frequency of condomless sex, and partner numbers among transgender women in China.

METHODS: Participants were recruited from 2 Chinese cities using both online and offline methods. Transgender women were randomly assigned to receive an HIVST intervention. Data from the previous 3 months were collected at baseline, 3 months, and 6 months. The primary outcome was the mean change in the number of HIV tests among transgender women during the 6-month follow-up. An intention-to-treat analysis was conducted. The statistical analysis used analysis of covariance and linear mixed-effects models.

RESULTS: From February to June 2021, and 255 transgender women were recruited, of which only 36.5% (93/255) had a steady job, and 27.1% (69/255) earned less than US $414.9 of income per month. They were randomly assigned to the intervention (n=127) and control (n=128) groups. At 6 months, the mean number of HIV tests was 2.14 (95% CI 1.80-2.48) in the intervention group and 1.19 (95% CI 0.99-1.40) in the control group (P<.001), with increases of 0.84 (95% CI 0.54-1.14) and 0.11 (95% CI -0.19-0.41) over 6 months, respectively. The net increase was 0.73 (95% CI 0.31-1.15; P<.001), with a similar adjusted result. No significant differences in the frequency of condomless sex or partner numbers were observed between the 2 groups.

CONCLUSIONS: HIVST is an effective strategy for enhancing regular HIV testing behavior among transgender women in China. This strategy should be combined with measures to address the financial vulnerability of the transgender women community to reduce subsequent risk behaviors, including condomless sex.

TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2000039766; https://www.chictr.org.cn/showproj.html?proj=61402.

PMID:39471367 | DOI:10.2196/58591

Eye Contact Lens. 2024 Oct 29. doi: 10.1097/ICL.0000000000001139. Online ahead of print.

ABSTRACT

OBJECTIVES: To investigate the referral and management patterns of patients with keratoconus among primary eye care practitioners in Ghana and Nigeria.

METHODS: A questionnaire adapted from previous studies was modified and created using Google Forms. The online survey was distributed to prospective participants using e-mails and other social media platforms. Data were analyzed using the Statistical Product and Service Solutions software (version 25.0; IBM Corp, Armonk, NY; Released 2017).

RESULTS: One hundred and sixty-nine optometrists responded to the survey (61.54% from Nigeria and 38.46% from Ghana). Most (88.6%) practiced without corneal topographers. Most respondents (77.7%, n=136) reported not fitting rigid gas-permeable (RGP) contact lenses in a year and 68% were willing to refer for contact lens fitting to another practitioner. The major barriers to RGP fitting were lack of experience (44.4%, n=72), cost to practice (15.4%, n=25), and other reasons (12.4%), whereas 27.8% (n=45) preferred not to answer. Seventy-six percent of respondents (n=133) were willing to fit RGPs if the respondents received the training to do so. About half of the respondents (53.8%) reported progression of cornea signs as the reason for referral to an ophthalmologist. Half of the respondents (n=51.4%) did not have a cornea surgeon in the area the respondents practiced, and 76.3% reported not comanaging patients at all with ophthalmologists.

CONCLUSION: This study highlights the current standard of care of patients with keratoconus in West Africa. The findings from this study suggest that clinical guidelines and further training of eye care practitioners in West Africa are needed to better manage patients with keratoconus.

PMID:39471349 | DOI:10.1097/ICL.0000000000001139

Clin Exp Dermatol. 2024 Oct 29:llae471. doi: 10.1093/ced/llae471. Online ahead of print.

ABSTRACT

BACKGROUND: Delusional parasitosis, also known as Ekbom syndrome, is a poorly understood condition often surrounded by misinformation. Patients and their families frequently encounter skepticism regarding their experiences. This research aimed to create a patient information leaflet (PIL) with a patient centred approach and to gather feedback on its usefulness for sharing information and validating their experiences.

OBJECTIVE: To evaluate patient feedback on a newly developed PIL designed for individuals with delusional parasitosis, assessing its perceived usefulness and impact.

METHODS: A survey was administered to 18 patients before their appointments, incorporating the new PIL. The survey included questions on the leaflet’s clarity, usefulness, ability to validate patient experiences and other pointers, measured on a 10-point Likert scale (0 = No answer, 1 = Strongly Disagree, 10 = Strongly Agree). Data was analysed using descriptive statistics and factor analysis. Additionally, the final question allowed for written feedback, which was examined through thematic analysis.

RESULTS: The survey results revealed that the majority of patients were satisfied with the new PIL. Specifically, 94% agreed or strongly agreed that the leaflet was logical and easy to follow, 72% found it useful for understanding their condition, and 89% felt it validated their experiences. Mean scores for these concepts were 8.83, 7.61, and 7.78, respectively. Thematic analysis of written feedback highlighted themes of improved understanding but uncertainty around acknowledgement of experiences.

CONCLUSION: This new patient-centered PIL for delusional parasitosis was well-received, indicating its potential as a valuable tool for patients and their support networks. By addressing the specific needs and experiences of patients, the leaflet can improve communication and reduce the stigma associated with the condition. Future research should explore long-term impacts and the effectiveness of similar resources in other patient populations.

PMID:39471340 | DOI:10.1093/ced/llae471

Genetics. 2024 Oct 29:iyae171. doi: 10.1093/genetics/iyae171. Online ahead of print.

ABSTRACT

Multi-environment trials (METs) are crucial for identifying varieties that perform well across a target population of environments (TPE). However, METs are typically too small to sufficiently represent all relevant environment-types, and face challenges from changing environment-types due to climate change. Statistical methods that enable prediction of variety performance for new environments beyond the METs are needed. We recently developed MegaLMM, a statistical model that can leverage hundreds of trials to significantly improve genetic value prediction accuracy within METs. Here, we extend MegaLMM to enable genomic prediction in new environments by learning regressions of latent factor loadings on Environmental Covariates (ECs) across trials. We evaluated the extended MegaLMM using the maize Genome-To-Fields dataset, consisting of 4402 varieties cultivated in 195 trials with 87.1% of phenotypic values missing, and demonstrated its high accuracy in genomic prediction under various breeding scenarios. Furthermore, we showcased MegaLMM’s superiority over univariate GBLUP in predicting trait performance of experimental genotypes in new environments. Finally, we explored the use of higher-dimensional quantitative ECs and discussed when and how detailed environmental data can be leveraged for genomic prediction from METs. We propose that MegaLMM can be applied to plant breeding of diverse crops and different fields of genetics where large-scale linear mixed models are utilized.

PMID:39471330 | DOI:10.1093/genetics/iyae171

JMIR Public Health Surveill. 2024 Oct 29. doi: 10.2196/53218. Online ahead of print.

ABSTRACT

BACKGROUND: This study provides an update to the status of the COVID-19 pandemic in Canada building upon our initial analysis conducted in 2020 by incorporating an additional two years of data.

OBJECTIVE: First, we aim to summarize the status of the pandemic in Canada when the World Health Organization (WHO) declared the end of the public health emergency for the COVID-19 pandemic on May 5, 2023. Second, we use dynamic and genomic surveillance methods to describe the history of the pandemic in Canada and situate the window of the WHO declaration within the broader history. Third, we aim to provide historical context for the course of the pandemic in Canada.

METHODS: This longitudinal study analyzed trends in traditional surveillance data and dynamic panel estimates for COVID-19 transmissions and deaths in Canada from June 2020 to May 2023. We also used sequenced SARS-CoV-2 variants from the Global Initiative on Sharing All Influenza Data (GISAID) to identify the appearance and duration of variants of concern. For these sequences, we used Nextclade nomenclature to collect clade designations and Pangolin nomenclature for lineage designations of SARS-CoV-2. We used t-tests of dynamic panel regression coefficients to measure the persistence of COVID-19 transmissions around the WHO declaration. Finally, we conducted a one-sided t-test for whether provincial and territorial weekly speed was greater than an outbreak threshold of ten. We ran the test iteratively with six months of data across the sample period.

RESULTS: Canada’s speed remained below the outbreak threshold for eight months by the time of the WHO declaration ending the COVID-19 emergency of international concern. Acceleration and jerk were also low and stable. While the 1-day persistence coefficient remained statistically significant and positive (1.074, P-value <.001), the 7-day coefficient was negative and small in magnitude (-0.080, P-value .02). Furthermore, shift parameters for either of the two most recent weeks around May 5, 2023, were negligible (0.003 and 0.018, respectively, with P-values of .75 and .31), meaning the clustering effect of new COVID-19 cases had remained stable in the two weeks around the WHO declaration. From December of 2021 onward, Omicron was the predominant variant of concern in sequenced viral samples. The rolling t-test of speed equal to ten became entirely insignificant from mid-October 2022 onward.

CONCLUSIONS: While COVID-19 continues to circulate in Canada, the rate of transmission remained well below the threshold of an outbreak for eight months ahead of the WHO declaration. Both standard and enhanced surveillance metrics confirm that the pandemic had largely ended in Canada by the time of the WHO declaration. These results can inform future public health interventions and strategies in Canada, as well as contribute to the global understanding of the trajectory of the COVID-19 pandemic.

PMID:39471286 | DOI:10.2196/53218

Natl Health Stat Report. 2024 Aug 27;(208). doi: 10.15620/cdc/158328.

ABSTRACT

OBJECTIVE: This report presents national results from the National Post-acute and Long-term Care Study to describe providers and services users in seven major settings of paid, regulated post-acute and long-term care services in the United States.

METHODS: Data are from the 2020 National Post-acute and Long-term Care Study, which includes surveys of adult day services centers and residential care communities and administrative data from the Centers for Medicare and Medicaid Services on home health agencies, hospices, inpatient rehabilitation facilities, long-term care hospitals, and nursing homes.

RESULTS: The findings show variation in characteristics of the seven post-acute and long-term care settings. About 68,150 providers served roughly 7.3 million people in the United States; about one-half of these providers were residential care communities, and about one-quarter were nursing homes. The Northeast had a higher percentage of adult day services centers than other settings, the Midwest had a higher percentage of nursing homes, the South had a higher percentage of long-term care hospitals, and the West had a higher percentage of residential care communities. Among the settings, more registered nurses were employed in inpatient rehabilitation facilities and long-term care hospitals, and more licensed practical nurses in home health agencies and long-term care hospitals. The most common services were skilled nursing and therapeutic services. Adult day services centers had the highest percentage of users younger than age 65, while nearly one-half of hospice and nursing home users were age 85 and older. Adult day services centers had the highest percentage of other non-Hispanic and Hispanic users among the settings. The percentage of users with selected diagnoses and activities of daily living difficulties varied by setting.

CONCLUSION: The providers described in this report comprise a large share of the U.S. post-acute and long-term care industry. This report provides the most recent nationally representative information on these providers and services users and updates findings from previous National Center for Health Statistics reports.

PMID:39471284 | DOI:10.15620/cdc/158328

J Manag Care Spec Pharm. 2024 Nov;30(11):1308-1316. doi: 10.18553/jmcp.2024.30.11.1308.

ABSTRACT

BACKGROUND: Alternative funding programs (AFPs) seek to reduce health plan sponsor costs, for example by excluding specialty drugs from a beneficiary’s plan coverage and requiring patients to obtain medications through alternative sources (typically, the manufacturer’s patient assistance programs) via an AFP vendor as a third-party.

OBJECTIVE: To describe patients’ experiences and specialty medication access with AFPs.

METHODS: A survey method consisting of 26 optional single-choice and multiple-choice questions with branching logic divided across 5 sections (related to patient challenges with AFPs) was administered to patients recruited from an experienced AFP online patient panel and a patient advocacy group. The survey assessed patients’ awareness of AFPs from their employers, experience with the patient assistance program application process via the AFP vendor, timeliness of medication access (if granted), and/or the health impact of delay in access. All descriptive and exploratory subgroup analyses were conducted by disease area and reported income levels; statistical analyses were carried out for the exploratory analyses.

RESULTS: The final sample included 227 patients. Most patients (61% [136/223]) first heard of the AFP as part of their health benefit when trying to obtain their medication. Of 198 patients, 88% reported being stressed because of the medication coverage denial and the uncertainty of obtaining their medication. More than half of patients (54% [115/213]) reported being uncomfortable with the benefits manager from the AFP vendor. On average, patients reported waiting to receive their medication for 68.2 days (approximately 2 months); 24% (51/215) reported the wait for the medication worsened their condition and 64% (138/215) reported the wait led to stress and/or anxiety. Patients who indicated the wait time negatively affected them had considered a job change or left their job at a 3-5-fold higher rate than those who reported no impact from wait time. A significantly higher proportion of patients with hemophilia and other bleeding disorders reported receiving their prescribed medication less often than patients with other conditions (63% [19/30] vs 81% [52/64]; P = 0.022), whereas more patients with lower incomes (<$50,000 vs >$50,000) reported not receiving any medication (12% [7/57] vs 5% [7/129]; P = 0.657), although these differences were not significant.

CONCLUSIONS: Most patients who obtain their specialty medicines via AFPs reported being uncomfortable with the process and experiencing treatment delays, which may have been linked to disease progression, worsened mental well-being, and consideration of a job change. Employers should be aware of the potential downstream impacts on employee health, retention, and the employee-employer relationship when considering implementing an AFP into their health plan.

PMID:39471273 | DOI:10.18553/jmcp.2024.30.11.1308

J Manag Care Spec Pharm. 2024 Nov;30(11):1288-1297. doi: 10.18553/jmcp.2024.30.11.1288.

ABSTRACT

BACKGROUND: Type 1 diabetes mellitus (T1DM) is a prevalent chronic endocrine disorder and accounts for 5%-10% of all diabetes cases worldwide. T1DM can have a substantial impact on health care utilization. Although it is well known that individuals with diabetes are at a greater risk of mental health disorders, specific evidence addressing the health care burden of comorbid depression/anxiety in people affected by T1DM is lacking.

OBJECTIVE: To assess health care resource utilization (HCRU) among adults with T1DM and comorbid depression or anxiety.

METHODS: We identified individuals aged 18 to 64 with a T1DM diagnosis from January 1, 2017, to December 31, 2021, using a 25% random sample of the IQVIA PharMetrics Plus for Academics database. The index date was the date of the first medical claim with a T1DM diagnosis. Eligibility required continuous medical and prescription coverage for 12 months before (baseline) and after (follow-up) the index date. Comorbid depression/anxiety and baseline characteristics were assessed during the baseline period. The following 2 mutually exclusive groups were created: individuals with T1DM and comorbid depression/anxiety, and those with only T1DM. To balance baseline demographic and clinical characteristics between the groups, we implemented 1:1 propensity-score matching. We assessed all-cause, diabetes-related, and major adverse cardiovascular event-related HCRU during the follow-up period. Logistic (binary) and negative binomial (count) regression models examined the association between comorbid depression/anxiety and HCRU across types of health care settings.

RESULTS: Out of 6,491 eligible individuals with T1DM, 1,168 (18%) had either depression or anxiety. In the matched cohort of 2,314 individuals, those with T1DM and comorbid depression/anxiety had significantly higher odds of all-cause emergency department visits (odds ratio = 1.67; 95% CI = 1.39-2.00) and higher rates of physician office visits (incidence rate ratio = 1.37; 95% CI = 1.27-1.47) and other outpatient encounters (incidence rate ratio = 1.23; 95% CI = 1.13-1.34) than those with only T1DM. Findings were similar for diabetes-related and major adverse cardiovascular event-related HCRU.

CONCLUSIONS: Comorbid depression/anxiety among individuals with T1DM results in significantly higher HCRU than T1DM alone. The findings underscore the importance of effective management of comorbid depression/anxiety in the T1DM population.

PMID:39471271 | DOI:10.18553/jmcp.2024.30.11.1288

J Manag Care Spec Pharm. 2024 Nov;30(11):1248-1260. doi: 10.18553/jmcp.2024.30.11.1248.

ABSTRACT

BACKGROUND: Multiple sclerosis (MS) is a lifelong progressive neurological disease treated primarily with disease-modifying therapies (DMTs). Disease activity tends to decline as patients age. Midlife represents a crossroads where the risks of DMT may outweigh the benefits, prompting providers to consider DMT discontinuation to reduce treatment burden. However, real-world evidence on the impact of DMT discontinuation among midlife patients is lacking.

OBJECTIVE: To evaluate the association between DMT discontinuation and health care utilization among midlife patients with MS.

METHODS: Midlife patients with MS who received an injectable or oral DMT between 2001 and 2018 were identified from the MarketScan commercial claims database. DMT discontinuation, defined as a treatment gap exceeding 90 days in days supply, was the independent variable. Patients who discontinued DMTs had their index date set as the last gap day, whereas index dates for those who continued DMTs were matched based on the time distribution of index dates of discontinuers. Inpatient hospitalizations (all-cause, MS-related, and non-MS-related), emergency department (ED) visits (all-cause, MS-related, and non-MS-related), and relapse-related hospitalizations and outpatient visits were independently evaluated during the 365-day follow-up. Patients were observed until the occurrence of an event (depending on the model), deviation from the treatment group, disenrollment, death, end of follow-up, or data unavailability. Stabilized inverse probability of treatment weighting (sIPTW) was employed to balance the 2 groups. The associations between DMT discontinuation and each utilization outcome were estimated using Cox proportional hazard regression models with sIPTW.

RESULTS: Of 149,721 midlife patients with MS, 22.8% discontinued DMTs and 77.2% continued DMTs. Patients who discontinued DMTs had a higher cumulative incidence for all utilization outcomes during the 365-day follow-up than those who continued DMTs. Cox regression showed that DMT discontinuation was associated with a 10.3% and 24.9% higher rate of all-cause and non-MS-related inpatient hospitalizations, respectively, with no significant association found for MS-related hospitalizations. Patients discontinuing DMTs exhibited higher utilization rates for ED visits, with an increase of 21.3% for all-cause, 23.0% for MS-related, and 20.9% for non-MS-related visits compared with those who continued DMTs. We also observed a 15.9% and 52.1% higher rate of relapse-related hospitalizations and outpatient visits associated with DMT discontinuation, respectively.

CONCLUSIONS: This study revealed that DMT discontinuation was associated with higher health care services utilization among midlife patients with MS, especially relapse-related outpatient visits. DMT discontinuation during midlife may be premature, and DMTs may still be necessary to reduce health care utilization.

PMID:39471270 | DOI:10.18553/jmcp.2024.30.11.1248